Key Points
- Pablo Cagnoni, Incyte’s President & Global Head of R&D, sold 18,667 shares at an average of $96.50 under a pre‑arranged Rule 10b5‑1 plan, netting about $1.8M and reducing his stake by roughly 6.6%, per an SEC filing.
- Incyte missed quarterly EPS ($1.80 vs. $1.96 estimate) but revenue grew 27.8% to $1.51B; the company has a $19.15B market cap, P/E of 15.01, and a MarketBeat consensus rating of Hold with a $104.89 target.
- Positive clinical and partnership news—new Phase 3 tafasitamab data presented at ASCO and a collaboration with Adagene on colorectal cancer—could support future label expansion and longer‑term revenue upside.
Incyte Corporation (NASDAQ:INCY - Get Free Report) insider Pablo Cagnoni sold 18,667 shares of the company's stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $96.50, for a total transaction of $1,801,365.50. Following the transaction, the insider owned 262,692 shares of the company's stock, valued at $25,349,778. This represents a 6.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Incyte Stock Down 0.7%
Incyte stock opened at $96.22 on Wednesday. The company has a 50-day simple moving average of $96.37 and a 200-day simple moving average of $98.39. The firm has a market capitalization of $19.15 billion, a P/E ratio of 15.01, a P/E/G ratio of 0.77 and a beta of 0.85. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 3.32. Incyte Corporation has a one year low of $56.77 and a one year high of $112.29.
Incyte (NASDAQ:INCY - Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 EPS for the quarter, missing the consensus estimate of $1.96 by ($0.16). The firm had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.35 billion. Incyte had a return on equity of 26.34% and a net margin of 25.03%.The firm's revenue was up 27.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.43 EPS. As a group, equities analysts expect that Incyte Corporation will post 6.55 earnings per share for the current year.
More Incyte News
Here are the key news stories impacting Incyte this week:
- Positive Sentiment: Incyte highlighted new Phase 3 tafasitamab data at the 2026 ASCO meeting, which could support future approval/label expansion and longer-term revenue upside for its oncology franchise. ASCO Tafasitamab Data
- Positive Sentiment: Incyte entered a collaboration with Adagene to evaluate a combo therapy for colorectal cancer, broadening its clinical pipeline and partnership optionality in immuno-oncology. Adagene Partnership
- Positive Sentiment: Analysts and outlets continue to flag Incyte as a value play given recent pullbacks versus fundamentals, which may attract value-focused buyers over time. Value Stock Note
- Neutral Sentiment: RBC Capital modestly raised its price target to $95 from $92 — a small analyst tweak that is unlikely to drive large moves but signals modest incremental confidence. RBC PT Raise
- Neutral Sentiment: Preview coverage notes Incyte is expected to report earnings growth next week, but some commentary suggests the company lacks the setup for a clear beat — adding short-term earnings uncertainty. Earnings Preview
- Neutral Sentiment: Recent analyst and media pieces are debating valuation after mixed returns; these discussions can temper momentum but don't change fundamentals immediately. Valuation Assessment
- Negative Sentiment: Pablo J. Cagnoni, Incyte’s President & Global Head of R&D, sold 18,667 shares under a pre-arranged Rule 10b5-1 plan at about $96.50 (≈$1.8M). The disclosed sale reduced his ownership by ~6.6% and is being cited by traders as a near-term negative signal despite the 10b5-1 context. Insider Sale / SEC Filing
Hedge Funds Weigh In On Incyte
Large investors have recently made changes to their positions in the business. Elyxium Wealth LLC bought a new position in shares of Incyte during the 4th quarter valued at about $28,000. Smithfield Trust Co lifted its stake in Incyte by 135.0% during the fourth quarter. Smithfield Trust Co now owns 282 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 162 shares in the last quarter. Harbor Capital Advisors Inc. purchased a new stake in Incyte during the third quarter valued at about $26,000. Root Financial Partners LLC purchased a new stake in Incyte during the third quarter valued at about $28,000. Finally, University of Texas Texas AM Investment Management Co. purchased a new stake in Incyte during the fourth quarter valued at about $35,000. Institutional investors own 96.97% of the company's stock.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on INCY. Stifel Nicolaus upped their price objective on shares of Incyte from $119.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, February 11th. Weiss Ratings raised shares of Incyte from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, April 1st. Wells Fargo & Company reduced their price objective on shares of Incyte from $107.00 to $101.00 and set an "equal weight" rating for the company in a report on Wednesday, February 11th. Morgan Stanley set a $102.00 price objective on shares of Incyte in a report on Wednesday, February 11th. Finally, Wall Street Zen downgraded shares of Incyte from a "strong-buy" rating to a "buy" rating in a report on Saturday, February 14th. Ten research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $104.89.
Check Out Our Latest Analysis on INCY
Incyte Company Profile
(
Get Free Report)
Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company's research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.
The company's flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
